NSE-listed companies investing in backward integration and API manufacturing capacity to reduce India's dependence on Chinese pharmaceutical ingredients — from PLI-backed steroidal API production to advanced intermediates for chronic therapies.
Sectors represented: Healthcare
Pharmaceutical Ingredient (API) industry through expanding. manufacturing capabilities, robust regulatory standards. and deeper integration into global pharmaceutical supply. chains. rmaceutical Ingredient (API) industry through expanding. manufacturing capabilities, robust regulatory standards. and deeper integration into global pharmaceutical supply. chains.
Growth is driven at one end by the. pharmaceutical sector's steady demand for reliable,. high-quality shells, and at the other by the rapid. expansion of nutraceuticals and wellness products, currents. Growth is driven at one end by the. pharmaceutical sector's steady demand for reliable,. high-quality shells, and at the other by the rapid. expansion of nutraceuticals and wellness products,.
India's cost-competitiveness, regulatory. track record, and strategic positioning as a trusted alternative. to China continue to attract global pharmaceutical companies. seeking to diversify their API sourcing. Rise of Biologics &. High-Potency APIs record, and strategic positioning as a trusted alternative. to China continue to attract global pharmaceutical companies.
The company is positioning itself to capture sustainable growth. through organisational integration, strategic portfolio diversification, and a continued focus on manufacturing excellence, delivering. long-term value to its stakeholders. Growth Drivers. Expansion in Speciality and High-Value APIs.
Although the CDMO API market is dominated by small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing. backward integration to mitigate the pricing pressure. small. molecules, higher growth is expected in the segments of high-. potency APIs and large molecules. The industry is increasing.
E x p e c t e d Increase in average o utsourcing penetration. US a c c o u n t s for 40-45% of C D M O markets. Eligible for Manufacturing. Controlled S u b s t a n c e s. C o m pl ie d to cater to. Government Supplies. 32.1. 44.7 in average o utsourcing penetration. US a c c o u n t s for 40-45% of C D M O markets. Eligible for Manufacturing. Controlled S u b s t a n c e s.
Increased propensity to outsource manufacturing of intermediates & APIs. ◼Enables asset light model and ability to focus on development of novel products for venture. capital backed start-ups. ◼Provides cost advantages and supply chain efficiencies g of intermediates & APIs. ◼Enables asset light model and ability to focus on development of novel products for venture. capital backed start-ups.
Strategic initiatives. such as the Production-Linked Incentive (PLI) scheme, along. with investments in bulk drug parks and API manufacturing. infrastructure, are enhancing domestic capabilities in active. pharmaceutical ingredient and formulation production,. thereby improving supply chain resilience and reducing. import dependence. infrastructure, are enhancing domestic capabilities in active.
Manufacturer from India. ➢Our Business Model. ➢Our Key Products and their Application. ➢Our Products. ➢Capex. ➢Our strategy and outlook. ➢Industry Overview. Advanced Pharma intermediate vanced Intermediate. Manufacturer from India. ➢Our Business Model. ➢Our Key Products and their Application. ➢Our Products. ➢Capex. ➢Our strategy and outlook. ➢Industry Overview. Advanced Pharma intermediate.
Generic manufacturers. in this space face high volatility. and heavy dependence on. outsourced intermediates. Market Context. The Indian pharmaceutical industry. is valued at USD 60 bn, with the API. segment comprising USD 15 bn. Approximately USD 4 bn of the API. segment relies on imports, underlining mediates. Market Context. The Indian pharmaceutical industry.
Unichem in its journey of several decades, also have the privilege to partner. with renowned pharmaceutical companies in offering third-party manufacturing services a comprehensive range of pharmaceutical. products tailored to the specific requirements of its clients. This association stands as a testament to its reliability, trustworthiness and. commitment to delivering excellence.
Going for. ward, margin sensitivity persists,. necessitating continued focus on product mix. optimization and geographic diversification to mitigate. concentration risk. B. API (Active Pharmaceutical Ingredients) Industry ivity persists,. necessitating continued focus on product mix. optimization and geographic diversification to mitigate. concentration risk. B.
From procurement to production till sales. have a strong foundation and sound setup. Backward integration ensures cost-. efficient manufacturing – Higher. Profitability pply and revenue. Cost Leadership. From procurement to production till sales. have a strong foundation and sound setup. Backward integration ensures cost-. efficient manufacturing – Higher. Profitability. 26. Diversification.
Product/Portfolio :. - Immuno-suppressants. - Limited Competition. products. - Backward integration of. IF/DF. State-of-Art, EU/TGA. approvedPlant. withEnhancedCapacity. APIs Business: Business Strategy and Way Forward. 31. . High value, low volume, nicheAPIs. . Mature stable molecules - Backward integration of. IF/DF. State-of-Art, EU/TGA. approvedPlant. withEnhancedCapacity.
Crores of Foreign Direct Investment. (FDI) into the pharmaceutical sector up. to September 2025, a measure of how. investors read the sector's prospects. The Production Linked Incentive (PLI). Scheme for Bulk Drugs has run ahead. of its investment commitments. aceutical sector up. to September 2025, a measure of how. investors read the sector's prospects. The Production Linked Incentive (PLI).